Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin vs exercise to reduce arterial stiffness in middle-aged and older adults
ChiCTR2300079001Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of terazosin in atherosclerosis, arteriosclerosis, coronary arteriosclerosis and 1 more (3 arms), sponsored by Xijing Hospital. Primary endpoint: Brachial-ankle pulse wave velocity. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
terazosin
03
Conditions
atherosclerosisarteriosclerosiscoronary arteriosclerosishypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2300079001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079001.